Professor David Celermajer has been Group Leader of the Clinical Research Group since 1994 and in 2003 was appointed as Clinical Director of HRI. In 2014, he was appointed as an Officer of the Order of Australia for services as a researcher and clinician in the field of cardiovascular disease. Prof Celermajer’s research areas of expertise include adult congenital heart disease, pulmonary hypertension, clinical cardiology and early origins of atherosclerosis.
Prof Celermajer has published over 300 scientific articles, as well as many review and editorial papers, totalling over 900 citations per year. This work includes the development and demonstration of a key ultrasound imaging technique, Flow Mediated Dilatation. This procedure is now used worldwide to measure endothelial function to detect the early onset of vascular diseases such as atherosclerosis. More recently Prof Celermajer has been a leading clinician-scientist researching Adult Congenital Heart Disease, an emerging patient group with complex care needs. This work has been highly transitional. Prof Celermajer founded DC Devices Pty Ltd (DC Devices Inc in the USA), which aims to commercialise a device for the treatment of heart failure.